In the following video, Motley Fool health-care analyst David Williamson takes a continuing look at the best-performing stocks in health care for this past January. In this video, he highlights MAP Pharmaceuticals (UNKNOWN:MAPP.DL), up 58% last month because of a buyout coming from its marketing partner, Allergan (UNKNOWN:AGN.DL). In the video, David tells us why MAP's key product, an inhaled migraine medication called Levadex, could be an excellent synergistic win for Allergan even though the FDA rejected the drug last March, and why Allergan is much more than the company known for Botox.